Jul. 22 at 6:27 PM
$ACRV "ACR-2316 is currently in a Phase 1/2 clinical study advancing toward the dose expansion phase. Initial observations have shown tumor shrinkage, including PRs, and durable clinical benefit in subjects with small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), and adenosarcoma NSCLC (adNSCLC), AP3-predicted tumor types not previously shown to be sensitive to other clinical WEE1 or PKMYT1 inhibitors".
https://ir.acrivon.com/news-releases/news-release-details/acrivon-highlight-power-its-ap3-platform-streamlined-pathway